Prof. Raphaëlle Luisier is a computational biologist with over a decade of interdisciplinary research in RNA biology and its role in complex human disorders. She earned her Master’s degree in Bioengineering and Biotechnology from the Swiss Federal Institute of Technology in Lausanne (EPFL) in 2009, followed by a PhD in Bioinformatics from the University of Basel in 2013. Since 2019, Prof. Luisier has led a research group at Idiap, an AI research institute, developing cutting-edge methods for the integrative analysis of molecular, clinical, and imaging data. Her expertise at the intersection of computational biology and RNA biology in disease contexts has led to significant breakthroughs in understanding the role and regulation of mRNA's non-coding regions in both physiology and disease. Notably, she identified aberrant intron retention as the earliest detectable molecular event in amyotrophic lateral sclerosis (ALS) and discovered the universal nuclear-to-cytoplasmic mislocalization of the SFPQ protein across the full spectrum of ALS. The overarching goal of her work is to revolutionize the understanding, prediction, and treatment of complex human disorders such as neurodegenerative diseases and cancer, leveraging an RNA-centric perspective. By developing cutting-edge AI technologies in collaboration with experts labs in AI and clinicians, her research aims to unravel the intricate molecular and cellular mechanisms driving these diseases, paving the way for innovative therapeutic strategies.